个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Development of inhibitors targeting glycogen synthase kinase-3β for human diseases: Strategies to improve selectivity.

| 认领 | 导出 | |

文献详情

资源类型：
Pubmed体系：
作者：
Wei Junxia[1] * ; Wang Jiaxing[2] * ; Zhang Jifa[1] * ; Yang Jinliang[1] ; Wang Guan[1] ; Wang Yuxi[1,3,*1] ;
机构： [1]Department of Respiratory and Critical Care Medicine, Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, Innovation Center of Nursing Research, Nursing Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China [2]Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, 38163, Tennessee, United States [3]Precision Medicine Key Laboratory of Sichuan Province & Precision Medicine Research Center, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China
出处：
DOI： 10.1016/j.ejmech.2022.114301
ISSN：

关键词： GSK-3β Inhibitors Selectivity Cancer treatment

摘要：
Glycogen synthase kinase-3β (GSK-3β) is a conserved serine/threonine kinase that participates in the transmission of multiple signaling pathways and plays an important role in the occurrence and development of human diseases, such as metabolic diseases, neurological diseases and cancer, making it to be a potential and promising drug target. To date, copious GSK-3β inhibitors have been synthesized, but only few have entered clinical trials. Most of them exerts poor selectivity, concomitant off-target effects and side effects. This review summarizes the structural characteristics, biological functions and relationship with diseases of GSK-3β, as well as the selectivity profile and therapeutic potential of different categories of GSK-3β inhibitors. Strategies for increasing selectivity and reducing adverse effects are proposed for the future design of GSK-3β inhibitors.Copyright © 2022 Elsevier Masson SAS. All rights reserved.

基金：
This review was supported by National Natural Science Foun- dation of China (82073318, 22177083, 81903502), Sichuan Science and Technology Program (2019YFS0003), National Major Scientific and Technological Special Project for Significant New Drugs Development (2018ZX09201018-021), and West China Nursing Discipline Development Special Fund Project, Sichuan University (Grant HXHL21011).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类 | 1 区 医学
小类 | 1 区 药物化学
最新[2023]版：
大类 | 2 区 医学
小类 | 1 区 药物化学
第一作者：
第一作者机构： [1]Department of Respiratory and Critical Care Medicine, Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, Innovation Center of Nursing Research, Nursing Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China
共同第一作者：
通讯作者：
通讯机构： [1]Department of Respiratory and Critical Care Medicine, Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, Innovation Center of Nursing Research, Nursing Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China [3]Precision Medicine Key Laboratory of Sichuan Province & Precision Medicine Research Center, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China [*1]Department of Respiratory and Critical Care Medicine, Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, Innovation Center of Nursing Research, Nursing Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China. .
推荐引用方式(GB/T 7714)：
Wei Junxia,Wang Jiaxing,Zhang Jifa,et al.Development of inhibitors targeting glycogen synthase kinase-3β for human diseases: Strategies to improve selectivity.[J].European journal of medicinal chemistry.2022,236:114301.doi:10.1016/j.ejmech.2022.114301.
APA：
Wei Junxia,Wang Jiaxing,Zhang Jifa,Yang Jinliang,Wang Guan&Wang Yuxi.(2022).Development of inhibitors targeting glycogen synthase kinase-3β for human diseases: Strategies to improve selectivity..European journal of medicinal chemistry,236,
MLA：
Wei Junxia,et al."Development of inhibitors targeting glycogen synthase kinase-3β for human diseases: Strategies to improve selectivity.".European journal of medicinal chemistry 236.(2022):114301

相关文献

[1]Glycogen synthase kinase 3β in tumorigenesis and oncotherapy (Review). [2]Glycogen synthase kinase 3β in tumorigenesis and oncotherapy (Review). [3]IL-8 protects prostate cancer cells from GSK-3β-induced oxidative stress by activating the mTOR signaling pathway. [4]The Role of m6A Epigenetic Modification in the Treatment of Colorectal Cancer Immune Checkpoint Inhibitors. [5]The Role of m6A Epigenetic Modification in the Treatment of Colorectal Cancer Immune Checkpoint Inhibitors. [6]Discovery of fused benzimidazole-imidazole autophagic flux inhibitors for treatment of triple-negative breast cancer [7]Safety and efficacy of neoadjuvant treatment with immune checkpoint inhibitors in esophageal cancer: real-world multicenter retrospective study in China. [8]The Role of Natural Products from Herbal Medicine in TLR4 Signaling for Colorectal Cancer Treatment [9]Recent research and development of inhibitors targeting sentrin-specific protease 1 for the treatment of cancers [10]Safety and Efficacy of Programmed Cell Death 1 and Programmed Death Ligand-1 Inhibitors in the Treatment of Cancer: An Overview of Systematic Reviews

资源点击量：52808 今日访问量：0 总访问量：4561 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号